Dacarbazine
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
Alkylating agent (methylmelamine)
Hexalen · ALT
Alkylating agent (methylmelamine) · approved 1990 · 3 citations
Largely superseded — little used in modern platinum-resistant ovarian-cancer regimens; ~2–3 papers/year over the last five years. Intrinsic renal toxicity is mild and not well established as an independent entity.
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Oral melamine antineoplastic for ovarian cancer; dose-limiting toxicities are neurologic and GI, with only mild, reversible renal changes reported.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Altretamine is not regarded as substantially nephrotoxic. Mild, generally reversible elevations in serum creatinine have been noted in trials, but the dose-limiting toxicities are gastrointestinal (nausea/vomiting), neurologic (peripheral and central neurotoxicity) and hematologic. No reliable renal incidence figure is established, and reported renal changes are confounded by frequent combination with cisplatin.Source: Lee et al., Drugs 1995 (renal effects mild, confounded by cisplatin); not quantified
Mild creatinine changes tend to occur during cycles and reverse after dosing, with poorly defined timing.
Distilled from: “Any mild creatinine change tends to occur during cycles and to reverse after dosing; timing is not well defined.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Methylmelamine that requires hepatic microsomal N-demethylation to generate reactive methylol and formaldehyde intermediates; these are thought to act as alkylating species damaging DNA, though it is not directly cross-resistant with classical alkylators.
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Class-level context for the major non-renal toxicities of the Alkylating agent (methylmelamine) class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
3 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 27 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
27 total FAERS reports is below the 50 this atlas requires before quoting an odds ratio, so report counts are shown instead of RORs and none of these counts as a signal. A phenotype missing below was queried and never cleared even the nominal CI bar, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
27 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2 of the 27 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. Showing the top 10 of 11 classified systems; 1 lower-ranked system is not drawn. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Altretamine (hexamethylmelamine) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
Emcyt · Hormonal–alkylating conjugate
Fluid retention, edema and thromboembolism.
Blenoxane · Antitumor antibiotic
Renally excreted (~2/3 in urine); half-life rises exponentially below CrCl 25-35 — exposure/clearance issue amplifying pulmonary toxicity, not a direct nephrotoxin.
Elspar · Enzyme
Rare AKI; pancreatitis-mediated.
Welireg · HIF-2α inhibitor
Anemia/hypoxia; emerging renal profile in VHL/RCC.
Halaven · Microtubule inhibitor
Reduced clearance in renal impairment.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.